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NEUROLOGICAL DISCREPANCIES
Neurological Discrepancies between Bipolar Disorder,
Schizophrenia and Schizoaffective Disorder

Introduction
As neurological research advances, so does the understanding of how disorders and
diseases develop and how they can be treated. The debate of how mental disorders develop has
been ongoing and complicated, as there is still no clear understanding of whether disorders are
caused by genetic or neurological predispositions, familial upbringing, or whether they arise as
one matures and a life occurrence triggers the onset. Understanding the cause of a disorder is
crucial to determining how to treat it. For example, for a long time psychologists tried to
convince society that suicidal depression is solely caused by a deficiency in serotonin, but plenty
of research has provided counterarguments that there is a complex distinction in brain activity in
people with depression as opposed to healthy individuals (Lacasse & Leo, 2005). As a result of
this research, the way in which depression is treated has improved, as there is a more obvious
importance of combining medication and psychotherapy in various intensities based on the
individual’s needs. Other disorders have been identified as needing more nuanced treatment
plans, and some of these disorders have been identified as somewhat similar in their
characteristics and forms of treatment. Three disorders in particular have been highlighted for
sharing brain functioning patterns and symptoms: bipolar disorder (BPD), schizophrenia (SZP),
and schizoaffective disorder (SAD).
The research conducted in this thesis is part of an ongoing study at the Olin
Neuropsychiatric Research Institute (ONRC) at the Institute of Living in Hartford, CT called the
Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Researchers across the
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United States are included in the B-SNIP study to determine the biological explanation for the
development of BPD, SZP, and SAD (Tamminga et al., 2013).

Psychological Symptoms of BPD, SZP, and SAD
BPD is characterized by fluctuations between depression and mania, with transitions
ranging from days to months. In depressive states, the individual may have little interest in
regular daily activities and they may become more reclusive. In manic states, an individual may
become more creative and impulsive; they may be more inclined to participate in reckless
activities such as gambling and drugs or use creative outlets such as painting or playing
music.
SZP is a disorder that still has no known cure. It is characterized by the addition of
symptoms atypical of normal behavior (positive symptoms) and removal of typical symptoms
(negative symptoms). Positive symptoms include delusions, hallucinations, and thought
disorder, whereas negative symptoms include a lack of affect, social isolation, and memory loss.
Finally, SAD is characterized by fluctuations between severe and more subdued symptoms,
including hallucinations, delusions, low interest in daily activities, impulsivity, and reduced
emotions. It is typically diagnosed if the individual exhibits both SZP symptoms and symptoms
of a mood disorder such as depression.
As one can see, these disorders share many symptoms. BPD and SAD both have swings
between high and low mood and motivation. SZP and SAD both have delusions and
hallucinations. Arguably, one can say that BPD and SZP are also very similar in that they both
display low moods and social isolation at times, which are indicators of depression. With these
similar symptoms, one can predict that there is similar brain activity between these disorders, and
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the difference in brain activity when compared to control groups is likely similar. SAD has been
theorized to be either a variant of the other two disorders or to be a part of a spectrum of
psychotic mood disorders (Mancuso et al., 2015). Over the past couple decades, many studies,
some of which will be introduced later, have been conducted to attempt to come to a concise
agreement on the distinction between these disorders, or lack thereof. Though the results of
these studies generally found clear differences reinforcing the distinctions between these
disorders, the explanations for their cause is still unclear.

Treatment of BPD, SZP, and SAD
Since the cause of these disorders is still not confirmed, the best method of treatment
is also not yet known. This is the main concern regarding research on the neurological cause
of BPD, SZP, and SAD. These disorders individually affect 0.5% to 1% of the United States
population. Though some patients do receive successful treatment, there are still individuals
who may be misdiagnosed, and thus treated improperly. For example, in a study conducted by
Cascade et al. (2009), they found that 22% of individuals with SAD only receive
antipsychotics, 20% receive both antipsychotics and mood medication, and 18% receive
antipsychotic, mood, and antidepressant medication. Other individuals receive even more
medications to account for anxiety or other problems. Since it is still unclear whether SAD
should even be considered an entirely distinct disorder in the DSM, it is also unclear whether
the best form of treatment is related to that of SZP or BPD, and therefore individuals with
SAD can receive a range from one to even five medications for the one disorder. It is not
sustainable for an individual to be so heavily dependent on multiple medications in order to
lead a normal life.
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The symptoms and neurological functioning of BPD is better understood, but the range
of treatments still varies greatly as well. A study conducted by Jann (2014) found that over
75% of individuals with BPD take their medication less than 75% of the time. Although mood
stabilizers, such as lithium, tend to be the main form of treatment for the disorder, atypical
antipsychotics are also occasionally used. This range of treatments is generally caused by the
range in manic and depressive symptoms that each individual experiences.
Finally, individuals with SZP are generally recommended to follow a well-regulated
pathway of treatment. According to Patel et al. (2014), drug treatment and therapy should start
as soon as possible after the first psychotic episode occurs. Second-generation atypical
antipsychotics are typical for the first medication. Starting a combination of medications is
only recommended in the later stages of the disorder development. However, 10-30% of
individuals with SZP appear to be resistant to the effects of antipsychotic medication, and thus
Clozapine is recommended, though individuals who take this medication have to be carefully
monitored for the risk of developing hypotension.
The form of treatment for each disorder depends on the symptoms and individuality of
each patient, but this also means that the pathway to becoming healthy is different for every
individual. Some people cannot be treated easily, which is unfair to them. Just because an
individual’s neurological and psychological functioning are impaired, it does not mean that
they are individuals incapable of participating as active citizens of their communities . The
goal of research such as that which is conducted in this thesis is to further assist in allowing
individuals with these disorders to live healthy lives. Since the pattern of neurological
functioning of each disorder is still unclear, psychiatrists cannot yet provide individuals with a
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clear form of treatment to target those neurological impairments and allow them to be healthy
again.

Previous findings of neurological differences
The cause and method of treatment is still a mystery for SZP. There does appear to be
significant disruption in functional connectivity in the prefrontal and medial temporal lobes,
which are involved in working memory and declarative memory, but this could be caused by any
combination of genetic and environmental factors (Karlsgodt et al., 2010). Another study found
strong evidence for abnormalities in the hippocampus and ventricles and for deficiencies in the
prefrontal cortex, but the risk factors for these problems also ranges from genetics to stressful life
encounters (Lawrie et al., 2008). No single conclusive results have been found yet to explain
what is specifically neurologically different for individuals with SZP as opposed to individuals
who are neurologically healthy or who have a different disorder.
BPD is a bit easier to treat due to a generally effective method of treatment and clear
characteristics of symptoms, though the neurological predisposition for the disorder is not yet
clear either. Some previous studies have found possible abnormalities in the prefrontal cortex,
striatum, and amygdala, and abnormalities in the cerebellar vermis and lateral ventricles can
develop later in life. The most substantial regions, however, to be functioning improperly is the
amygdala and other portions of the limbic network (Strakowski et al., 2005). It makes sense that
the brain regions involved in mood regulation are impacted in individuals with BPD, though not
all individuals with the disorder exhibit these neurological distinctions.
SAD is particularly difficult to understand as there are not yet many studies that have
found any conclusive evidence on what makes the disorder neurologically distinct from BPD and
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SZP. Articles on SAD generally redirect to those that only pertain to SZP, or they can include
both SAD and SZP in the article title but only discuss SZP in the majority of the results, such as
one article by Hoptman et al. (2005).
For the purpose of this thesis, it is necessary to analyze any type of overlap or differences
in neurological functioning between the disorders. Some previous studies have indeed found
some neurological similarities. One study compared the neurological differences between SZP
and BPD in a meta-analysis. They found 17 resultant ALE clusters, and both disorders exhibited
lower gray matter in the bilateral frontal gyrus, thalamus, left middle temporal gyrus, cingulate
gyrus, and caudate. Only SZP displayed reduced gray matter volume in the left amygdala and
insula, which led to the conclusion that both disorders have reduced gray matter volume in
regions throughout the brain, but SZP has additional reduced gray matter in the left hemisphere
(Yu et al., 2010). These reductions in volume may explain the negative impact on mood
regulation present in both disorders, particularly in SZP. Another study compared the biological
distinctions between BPD and SZP – the researchers found a lot of similarities in the risk loci,
but the copy number variation is less obvious in BPD (Harrison et al., 2018). These results
indicate that at the chromosomal level, the disorders exhibit similar differences in the gene
variation when compared to control groups, so it is possible that the biological reason for both
disorders is the same.
Since the analyses conducted in this thesis involve the functional connectivity of the
disorders, it is also necessary to see what previous researchers have found on the brain
connectivity of these disorders. Argyelan et al. (2014) studied resting-state fMRI images of BPD
and SZP. They found that individuals with SZP exhibit significantly lower overall connectivity
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between brain regions when compared to the control group, and BPD subjects had some
connectivity reduction, but this was more subdued from that of SZP subjects.
Finally, another group of researchers attempted to determine similarities in SAD and the
other two disorders. SAD was introduced as a distinct disorder 80 years ago, but the symptoms
and characteristics of the disorder are so similar to those of the other two so there is still debate
on whether it should be its own disorder, something between the two other disorders, or not an
official disorder at all. A paper written by Ellison-Wright and Bullmore (2010) analyzed 42
studies of subjects with SZP and BPD. They found gray matter volume reduction in SZP in the
frontal, temporal, cingulate, and insular cortices and the thalamus, and increased gray matter in
the basal ganglia. In BPD, they found gray matter volume reduction in the anterior cingulate
cortex and bilateral insula in BPD, a significant amount of this reduction in common with that of
SZP (Ellison-Wright & Bullmore, 2010). These results reinforce the potential explanation for the
reduction in mood regulation in the disorders. The function of the anterior cingulate cortex is
generally the regulation of autonomic body functions, which raises some unique questions on
whether BPD is also distinguished by a reduction in the ability to regulate functions such as heart
rate and blood pressure.
Further studies (Amann et al., 2016) (Bora et al., 2012) reached similar conclusions,
except that the distinctions were less obvious when the predominance of male patients was
accounted for in the SZP studies. Amann et al. (2016) conducted a study with 45 patients with
SAD, SZP, and BPD, to analyze how this third disorder could be compared with the other two
neurologically with fMRI scans. They found that SAD and SZP displayed brain volume
reduction in many corresponding regions, whereas individuals with bipolar disorder displayed no
reduction in brain volume as compared to controls (Amann et al., 2016). Since the results for
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BPD were found to be different from the other two disorders as compared to the previously
mentioned papers, there is still some lack of clarity about the cause of these disorders.
As these and other studies show, there are significant overlaps between the symptoms and
neurological functioning of individuals with SZP, SAD, and BPD. Analyses find some of the
same results, but there exist discrepancies in the brain regions that are found to be activated at
different intensities. This data leads to the question of whether these disorders should be labelled
as entirely distinct in the DSM. This question is important because categories of diagnosis lead to
individualized treatment plans, and if studies find that the neurological cause of these disorders is
similar, then the treatment for each of them should logically be similar as well.

Plan for thesis analysis
My research questions for this thesis are: At resting state, how are BPD, SZP, and SAD
neurologically distinct in their functional connectivity? How does this compare to the differences
between the psychosis biotypes? And how do covariates such as the usage of medication play a
role in the observed neurological differences?
Functional connectivity refers to the amount of connections that each voxel has with the
rest of the brain. High connectivity indicates high neurological functioning. fMRI scans can
show how components of the brain are functionally connected in order to accomplish tasks, and
this is observed by recording activation maps. This can be done with resting state images, and the
variations in fMRI signaling indicates strength of connectivity (Rogers et al., 2007). By
comparing the disorders and biotypes, a greater similarity in connectivity would be exhibited by
fewer areas of the brain lit up.
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Although fMRI images of subjects completing cognitive tasks certainly have their
benefits in conducting neurological research, resting-state images are equally important. An
article by Shen (2015) explained that observing the functional connectivity of resting-state brains
helps researchers understand how the brain works when it is just processing daily life. Certainly,
individuals with various neurological disorders complete cognitive tasks with different parts of
their brains, but at resting state, it is possible to see the ongoing neurological activity. As Shen
expressed, “Scientists do hope to use resting-state connectivity to help improve treatments for
neuropsychiatric patients who have already been diagnosed by other means” (Shen 2015). This is
the reason why resting-state images were used for the research conducted in this thesis. By
developing a better understanding of how the brain works at a resting state in individuals with
these disorders, we can determine more comprehensively what is neurologically malfunctioning
on a day-to-day basis and therefore develop a better treatment plan for these individuals.
In my thesis, I analyze fMRI images displaying the functional connectivity in individuals
with SZP, BPD, and SAD, and in individuals with biotype 1, 2, and 3 of individuals who exhibit
psychosis. This is part of a larger neurological study called the Bipolar Schizophrenia Network
on Intermediate Phenotypes (B-SNIP), which includes biological characteristics in the
comparison of neurological disorders. This inclusion allows for a more comprehensive
understanding of these psychosis-related disorders. The three biotypes indicate the severity of
psychosis, with psychosis defined as an inability to distinguish between reality and illusion.
Symptoms of psychosis include delusions, hallucinations, incoherent or inappropriate behavior,
and reduced socialization, motivation, and sleep. Biotype 1 includes the most severely impaired
individuals, biotype 2 exhibits moderate symptoms, and biotype 3 displays more subdued
symptoms. Previous studies have found that biotypes 1 and 2 display reduced gray matter
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throughout the cerebral cortex, whereas biotype 3 has reduced gray matter mostly in the regions
responsible for emotion regulation (Asher, 2015).
I theorize that there is significant difference in brain functional connectivity between the
three disorders, which leads to the belief that they should indeed be categorized as three distinct
disorders in the DSM. I also compare the three biotypes of these disorders to determine whether
there is a neurological difference between the three genetic categories, and I theorize that the
three biotypes are indeed distinct. This in turn leads to the conclusion that each disorder requires
its own unique treatment plan. In addition, I incorporate the usage of various types of medication
into the study to determine whether the difference in brain connectivity is due to the use of
medication or due to the presence of the disorder itself. Finally, I separate the subjects in the
study based on the location of the fMRI scan in order to determine whether each of the cities
diagnoses the disorder differently, and what impact this has on the brain connectivity found in
the individuals found in that city. The locations for the fMRI scans were in Baltimore, Boston,
Chicago, Dallas, Detroit, and Hartford.

Methods

Participants
1122 subjects from Baltimore, Boston, Chicago, Dallas, Detroit, and Hartford were
recruited for this study. Participants had fMRI scans taken at a resting state. Both male and
female subjects were formally diagnosed with the DSM-V with either BPD, SZP, and SAD.
Their ages ranged between 15 and 65. Family members of the subjects with the
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aforementioned disorders were allowed to participate. To create control groups, individuals
without any of the disorders were included and went through a screening process to ensure
that they qualified as a suitable control.

Preprocessing
VNC Viewer was used to access the database of information. DPARSF (Data Processing
Assistant for Resting-State fMRI) 4.4 Advanced Edition in DPABI (Data Processing & Analysis
for (Resting-State) Brain Imaging) was the program used in MATLAB to preprocess the fMRI
scans. This program has been found beneficial in previous research due to its ease of access
(Chao-Gan & Yu-Feng, 2010). The first preprocessing stage was spatial normalization, followed
by realignment, covariate regression, scrubbing, and distortion correction. The EPI functional
images of each subject were overlaid on an MRI field map to look for artifacts, and the realign
parameter was set to 3 mm to exclude subjects according to their maximum head motion.
The z score of each scan exhibits the standard deviation from the mean. To prevent the
data from being skewed, 120 subjects with z scores above 2 were removed. Unfortunately,
this resulted in all of the subjects from Boston to be removed during the preprocessing stages.
Non-parametric statistics were conducted with TFCE (Threshold-free Cluster
Enhancement) Toolbox in MATLAB, with 1000 permutations. This calculated a t value, creating
a null distribution. At the end of preprocessing, 629 subjects were available for use in the study,
as the fMRI images of the remaining subjects were not smoothed and straightened enough to
accurately compare with the images of other subjects. For the broad analysis of the subjects
based on their DSM diagnosis and biotype, all 629 subjects were used.
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Categorization
For simplicity, links were made using WinSCP to the data folder containing the fMRI
scans for each subject. Upon completion of the fMRI scans, an Excel spreadsheet was
produced containing the covariates and other information including age, sex, framewise
displacement, usage of antipsychotics, lithium, and mood regulators.
Initially, the subjects were divided in two separate studies by DSM diagnosis and
biotype. Subjects with BPD, SZP, and SAD were placed in three respective groups of scans for
the DSM study, and subjects with biotype 1, 2, and 3 were placed in three respective groups for
the biotype study. Controls were included in both studies. After screening out subjects whose
scans did not succeed in the preprocessing stages, there were 139 individuals with BPD, 104
with SAD, 158 with SZP, 103 with biotype 1, 137 with biotype 2, 161 with biotype 3, and 227
controls.
After dividing the subjects into their respective categories, additional comparisons
were made with the covariates introduced above. The fMRI scans of individuals who took
medication, for example, was compared with the mean of all the fMRI scans to determine the
difference in activity for those who took medication. Of those comparisons, antipsychotics usage
was the only covariate above found to be statistically significant for individuals who take this
medication as opposed to those who do not.
The DSM and biotype categories were then compared with antipsychotic usage included
as a covariate in an ANOVA analysis; no comparisons were statistically significant. Finally,
subjects who took antipsychotics were examined to find brain regions which were activated
more or less without considering DSM or biotype. The identified regions were then compared
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with subjects within each DSM and biotype categories without considering antipsychotic
usage.

Analysis
In SPM12, a one-way ANOVA was used as a factorial design to compare the DSM
disorders and the biotypes. Initially, site (Baltimore, Chicago, Dallas, Detroit, and Hartford), age,
sex, and framewise displacement were used as covariates. Antipsychotic usage was later added
as an additional covariate. In the factorial design of SPM12, variance was set to be unequal, and
there was no grand mean scaling and no ANCOVA. Model estimation was set up with
dependency on the model, and contrast manager was set up with dependency on model
estimation. Residuals were not written in model estimation. In contrast manager, the t-contrasts
for the DSM disorders were NC-BPD, NC-SAD, NC-SZP, BPD-SAD, BPD-SZP, and SADSZP. The t-contrasts for the biotypes were NC-1P, NC-2P, NC-3P, 1P-2P, 1P-3P, and 2P-3P.
Both positive and negative contrasts were conducted in order to determine the comparisons in
both directions for each contrast.
Other comparisons were conducted as well that were included in this study, using the
subjects from the studies above. This was done in order to further determine whether the
differences in brain connectivity for the individuals was due to their biotype or disorder, or
whether it was due to the use of various types of medication or another reason. We compared
individuals who took antidepressants with those who did not take antidepressants. This was done
with a two-sample t-test. In the factorial design, 183 subjects were on antidepressants and 439
were not. A t-contrast was done between the two groups. The same set-up was done for subjects
who took antipsychotics. 340 subjects took antipsychotics, whereas 282 did not. For a lithium
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study, 62 subjects were taking lithium and 560 were not. In a mood study, 190 subjects were on
mood regulation medication whereas 432 were not.
A multiple regression model was used for several other comparisons. In a cognitivesensorimotor study, we attempted to discern a significant difference in brain activity based on
cognitive and sensorimotor functioning. This was conducted with 627 subjects. A t-contrast was
done between the mean and cognitive results, and the mean and sensorimotor results. A PANSS
(positive and negative syndrome scale) multiple regression was done with 397 subjects. Finally,
a site regression model was set up, with 622 subjects in an f-contrast with a weights matrix of
4x9 to observe the main effect of site. Only in the sites regression were residuals produced in the
model estimation, and another f-contrast was done with the residual data to determine any
possible impact in site on the outcomes of the comparisons.
Due to the limited time to complete this research, age of onset was not considered as a
covariate, so there was no analysis conducted on how the age of onset impacted the neurological
data. A previous study (Tamminga et al., 2013) found that age of onset of these disorders had no
impact on the categorization of the subjects, and another study (Clementz et al., 2016) did not
include this covariate in their analysis of biotypes.
The ultimate goal of this thesis is to determine whether there are significant neurological
distinctions between the DSM disorders and the biotypes. The additional comparisons were done
in order to evaluate whether the neurological distinctions were due to the disorders themselves or
to outside influences such as medications or the site at which the fMRI scans took place.
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Results
The neuronal connectivity of each of the biotypes and disorders was compared with each
other and with the control group in order to determine the difference in what brain regions
exhibited high connectivity. Table 1 displays the differences between all of the DSM disorders,
Table 2 displays the regions of the biotypes, and Table 3 displays the differences of the
additional covariates that we focused on. We compared the usage of antipsychotics, lithium,
mood medication, and the PANSS scores to the mean in order to determine whether the
differences in connectivity were due to the disorder itself or to the use of medication.
The second column in each table indicates the minimum voxel size needed for brain
regions to be deemed significant. These values were determined through the clustsimreport
function in Matlab, in order to determine the smallest number of voxels needed in a cluster in
order to confirm that the brain activity was not due to chance (“AFNI Program”). The small
voxel sizes exhibited in Table 3 were due to the lack of a need for this report because of the low
number of any connectivity differences.
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Table 1: Significant brain regions in original study of comparison of DSM disorders. All
comparisons include covariates of site, age, sex, and framewise displacement.
Comparison
Cluster size Significant regions
Control – BPD
52
Medial frontal gyrus, anterior cingulate, precentral
gyrus, postcentral gyrus, cingulate gyrus, superior
temporal gyrus
BPD – Control
52
Superior frontal gyrus, uvula, declive
Control – SAD
30
Superior frontal gyrus
SAD – Control
30
No significance
Control – SZP
54
Postcentral gyrus
SZP – Control
54
Inferior parietal lobule, medial frontal gyrus,
angular gyrus
BPD – SAD
42
Middle temporal gyrus, middle frontal gyrus,
culmen, declive
SAD – BPD
42
No significance
BPD – SZP
34
Hippocampus, culmen
SZP – BPD
34
Anterior cingulate, cuneus
SAD – SZP
39
No significance
SZP – SAD
39
Supramarginal gyrus, inferior parietal lobule

Table 2: Significant brain regions in original study of comparison of biotypes. All comparisons
include covariates of site, age, sex, and framewise displacement.
Comparison
Cluster size Significant regions
Control – 1P
55
Superior temporal gyrus, postcentral gyrus, insula
1P – Control
55
Superior frontal gyrus, angular gyrus, precuneus
Control – 2P
42
Superior temporal gyrus
2P – Control
42
Superior frontal gyrus, middle frontal gyrus
Control – 3P
59
No significance
3P – Control
59
No significance
1P – 2P
30
No significance
2P – 1P
30
No significance
1P – 3P
22
No significance
3P – 1P
22
No significance
2P – 3P
30
Medial frontal gyrus
3P – 2P
30
No significance
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Table 3: Significant brain regions in each comparison of use of medication and of PANSS
(Positive and Negative Syndrome Scale). All comparisons include covariates of site, age, sex,
and framewise displacement.
Comparison
Cluster size Significant regions
Antipsychotics – Mean
72
Paracentral lobule, lingual gyrus, putamen,
cuneus, superior temporal gyrus
Mean – Antipsychotics
72
Superior frontal gyrus, supramarginal gyrus
Lithium – No Lithium
5
No significance
No Lithium – Lithium
5
No significance
Mood Medication – Mean 5
Putamen, insula
Mean – Mood Medication 5
Middle frontal gyrus, inferior occipital lobe,
precentral gyrus
PANSS Positive – Mean
5
No significance
PANSS Negative – Mean 5
No significance
PANSS Total – Mean
5
No significance
PANSS Mean – Positive
5
Postcentral gyrus
PANSS Mean – Negative 5
Precentral gyrus
PANSS Mean – Total
5
Middle temporal gyrus, postcentral gyrus,
supramarginal gyrus, insula, inferior parietal
lobule

Table 4: All of the comparisons in the tables above are reorganized here to determine overlap in
brain regions that exhibited greater connectivity.
Significant Regions
Comparisons
Total # Comparisons
Angular Gyrus
1P – Control, SZP – Control
2
Anterior Cingulate
Control – BPD, SZP – BPD
2
Cingulate Gyrus
Control – BPD
1
Culmen
BPD – SAD, BPD – SZP
2
Cuneus
SZP – BPD, Antipsychotic – Mean
2
Declive
BPD – Control, BPD – SAD
2
Hippocampus
BPD – SZP
1
Inferior Occipital Lobe
Mean – Mood Medication
1
Inferior Parietal Lobule
SZP – Control, SZP – SAD, PANSS
3
Mean – Total
Insula
Control – 1P, Mood Medication – Mean, 3
PANSS Mean – Total
Lingual Gyrus
Antipsychotics – Mean
1
Medial Frontal Gyrus
Control – BPD, SZP – Control, 2P – 3P
3
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BPD – SAD, 2P – Control, Mean – Mood
Medication
Middle Temporal Gyrus
BPD – SAD, PANSS Mean – Total
Paracentral Lobule
Antipsychotics – Mean
Precentral Gyrus
Control – BPD, Mean – Mood
Medication, PANSS Mean - Negative
Precuneus
1P – Control
Postcentral Gyrus
Control – BPD, Control – SZP, Control –
1P, PANSS Mean – Positive, PANSS
Mean – Total
Putamen
Antipsychotics – Mean, Mood
Medication – Mean
Superior Frontal Gyrus
BPD – Control, Control – SAD, 1P –
Control, 2P – Control, Mean –
Antipsychotics
Superior Temporal Gyrus Control – BPD, Control – 1P, Control –
2P, Antipsychotics – Mean
Supramarginal Gyrus
SZP – SAD, Mean – Antipsychotics,
PANSS Mean – Total
Uvula
BPD – Control
Middle Frontal Gyrus

3
2
1
3
1
5

2
5

4
3
1

The figures displayed below portray the brain regions that exhibited higher connectivity of the
first group over the second. Other regions may have appeared as well, but the regions below are
the largest. The comparisons found in each table that did not exhibit any significant regions are
not included in the selection of images.
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Figure 1: Control – Bipolar Disorder. Sagittal, coronal, and transversal images are all oriented to
exhibit the same (x, y, z) coordinates. The primary region that displayed greater connectivity in
the control group is the superior temporal gyrus, shown here. Minimum cluster size to indicate
significance is 52.

Figure 2: Bipolar Disorder – Control. Sagittal, coronal, and transversal images are all oriented to
exhibit the same (x, y, z) coordinates. The primary region that displayed greater connectivity in
BPD is the superior frontal gyrus. Minimum cluster size to indicate significance is 52.

Figure 3: Control – Schizoaffective Disorder. The region displayed here is the superior frontal
gyrus. Minimum cluster size to indicate significance is 30.
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Figure 4: Control – Schizophrenia. The most significant region, displayed here, is the postcentral
gyrus. Minimum cluster size is 54.

Figure 5: Schizophrenia – Control. The most significant region, displayed here, is the interior
parietal lobule. Minimum cluster size is 54.

Figure 6: Bipolar Disorder – Schizoaffective Disorder. Middle temporal gyrus. Minimum cluster
size is 42.
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Figure 7: Bipolar Disorder – Schizophrenia. The hippocampus is the most significant region with
greater connectivity in BPD. Minimum cluster size is 34.

Figure 8: Schizophrenia – Bipolar Disorder. The region displayed here is the cuneus and anterior
cingulate. Minimum cluster size is 34.

Figure 9: Schizophrenia – Schizoaffective Disorder. The region displayed here is the
supramarginal gyrus. Minimum cluster size is 39.

24

NEUROLOGICAL DISCREPANCIES

Figure 10: Control – 1P. The superior temporal gyrus exhibited greater connectivity in the
control group. Minimum cluster size is 55.

Figure 11: 1P – Control. The region displayed here is the superior frontal gyrus. Minimum
cluster size is 55.

Figure 12: Control – 2P. The region here is the superior frontal gyrus. Minimum cluster size is
42.
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Figure 13: 2P – Control. The region displayed here is the middle frontal gyrus. Minimum cluster
size is 42.

Figure 14: 2P – 3P. The region displayed here is the medial frontal gyrus. Minimum cluster size
is 30.

Figure 15: Mean – Antipsychotics usage. The region with greater connectivity in the control
group is the superior frontal gyrus. Minimum cluster size is 72.
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Figure 16: All DSM disorders (spmT_0001-0006, excluding 0002 in brown) overlaid with
antipsychotic/no antipsychotic (spmT_0002) comparison. Sagittal, coronal, and transversal
images are all oriented to exhibit the same (x, y, z) coordinates. The only significant region in
common between the antipsychotic comparison and at least one disorder is the superior temporal
gyrus. A cluster size of 30 was used.

Figure 17: All biotypes (spmT_0001-0006, excluding 0001 in brown) overlaid with
antipsychotic/no antipsychotic (spmT_0001 in brown) comparison. The only significant region
in common between the antipsychotic comparison and at least one biotype is the superior
temporal gyrus. A cluster size of 30 was used.
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Discussion
The initial study solely compared resting-state images displaying the connectivity
between DSM disorders and biotypes in order to determine whether there is significant
difference to deem each disorder and biotype as entirely distinct from one another. Resting-state
images were used as opposed to images during cognitive tasks because this research prioritized
gaining a better understanding of how the subjects’ brains worked when no stimuli were
introduced. By observing the resting state images, we can determine the ongoing neurological
functions of each disorder and can attempt to discern what is malfunctioning in this ongoing
daily functioning.
The selection of voxel size shown in all of the tables was done with a program called
clustsimreport in Matlab in order to determine how large each cluster should be to remove all of
the irrelevant noise. The program analyzes the amount of noise in each brain image and
determines the minimum number of voxels required in a cluster to ensure that the functional
connectivity is not due to chance (“AFNI Program”).
Table 1 indicates the comparisons between the DSM disorders. The data in this table
indicates there is a minor difference between the disorders, but this distinction is present
nonetheless. The comparison with the greatest number of regions that exhibit greater
connectivity is between BPD and the control group, with the control group having greater
connectivity in the medial frontal gyrus, anterior cingulate, precentral gyrus, postcentral gyrus,
cingulate gyrus, and superior temporal gyrus. BPD also exhibits greater connectivity than SAD
in the middle temporal gyrus, middle frontal gyrus, culmen, and declive. Finally, BPD exhibits
greater connectivity than SZP in the hippocampus, indicating the possibility of a greater ability
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to convert information to long term memory. The distinction between these disorders is
subjective in whether it indicates that these disorders should be labelled as distinct, at least from
a neurological perspective. There are not many brain regions that exhibit connectivity differences
between the disorders.
When specifically looking at the comparisons with SAD in Table 1, there are no brain
regions that exhibit greater levels of connectivity in SAD over the other groups. These results
may indicate that individuals with SAD do not have any brain regions that are connected more
strongly with the rest of the brain. In addition, when analyzing the regions that have greater
connectivity in the other disorders over SAD, it is possible that those regions are caused by the
covariates analyzed in Table 3. Control – SAD exhibits the superior frontal gyrus, but this region
is also found to be more strongly linked to the rest of the brain in the mean group over the
individuals who took antipsychotics in Table 3. BPD – SAD exhibits the middle temporal gyrus,
middle frontal gyrus, culmen, and declive. However, the middle temporal gyrus was identified in
the Mean – total PANSS comparison, and the middle frontal gyrus was identified to have greater
connectivity in the mean group over individuals who took mood medication. SZP – SAD
exhibits the supramarginal gyrus and inferior parietal lobule, but these regions are both found in
the Mean – total PANSS comparison as well.
Since individuals with SAD can take a range of medications that frequently include both
antipsychotics and mood medication (Cascade et al., 2009), and they also exhibit the positive
and negative psychotic symptoms that are analyzed in the PANSS scale, these overlaps in
brain regions are relevant. Perhaps the culmen and declive that we see has greater connectivity
in BPD over SAD is significant to understand the actual neurological difference between these
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disorders, but these regions are not known for substantial cognitive functioning. Both regions are
in the cerebellum, which is responsible for more autonomic functions.
Therefore, based on this perspective of the results in Tables 1 and 3, SAD is not
neurologically distinct from BPD or SZP. This supports the notion that these three disorders
should be set on a spectrum of psychosis disorders, rather than identifying SAD as an entirely
unique disorder. BPD and SZP do show some differences between each other regarding their
functional connectivity, so if these three disorders were set on a spectrum of psychosis disorders
in the DSM, they could be put on opposite sides. BPD exhibits greater connectivity in the
hippocampus and culmen, and SZP exhibits greater connectivity in the anterior cingulate and
cuneus. The two disorders also exhibit substantial differences in brain connectivity when
compared to the control group, indicating that there is indeed some unique functioning of these
disorders as opposed to neurologically healthy individuals.
To finalize the analysis of the DSM disorders, Figure 16 displays all of the comparisons
of BPD, SZP, and SAD and overlaid the images with the antipsychotics – mean comparison. The
purpose of this analysis was to determine whether there was any brain region that any or all of
the disorders overlapped with the use of antipsychotics, since the antipsychotics – mean
comparison in Table 3 included many brain regions. The only region that was relevant was the
superior temporal gyrus, as the antipsychotics – mean comparison overlapped with a few of the
DSM comparisons at this region. The superior temporal gyrus has been found to be a significant
region for schizophrenic individuals. SZP is frequently characterized by reduced P300 action
potentials in the brain, and the reduction in these potentials is positively correlated with gray
matter reductions in the left posterior superior temporal gyrus (McCarley, Shenton, &
O’Donnell, 1993). Although the superior temporal gyrus is not implicated in any SZP
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comparisons in this thesis, there is still some relevant overlap with the other disorders, and BPD
and SAD both exhibit some psychotic symptoms that are relevant to the research conducted by
McCarley. Since the brain connectivity differences are so unique for each disorder, these results
indicate that the use of antipsychotics does not impact all three disorders in the same way.
According to Table 2, there is no substantial difference between any of the biotypes.
Biotypes 1 and 2 appear to be neurologically distinct from the control group, but Biotype 3 does
not exhibit any difference. This portion of the results makes sense because Biotype 3 has the
most subdued intensity of psychosis, so it is the closest to a neurologically healthy individual’s
behavior. When comparing the functional connectivity of Biotypes 1 and 2 to Biotype 3, there is
no difference, which indicates that the mildest form of psychosis symptoms is not influenced by
any detectable difference in brain functioning. These results are in agreement with a previous
biotype study that found that Biotypes 1 and 2 differed significantly in their cognitive
functioning when compared to the control group, but Biotype 3 exhibited no difference
(Clementz et al., 2016).
The comparisons of Biotype 1 and 2 to the control group is similar as well. The superior
temporal gyrus has greater connectivity in the control group as opposed to both biotype groups,
and the superior frontal gyrus has greater connectivity in both of the biotype groups as opposed
to the control. However, Control – 2P only exhibits the superior temporal gyrus, and 2P –
Control only exhibits the superior frontal gyrus and middle frontal gyrus. For 1P, the biotype
with the most severe psychosis symptoms, the control group also shows greater connectivity in
the postcentral gyrus and insula, and 1P also exhibits greater connectivity in the angular gyrus
and precuneus. This data indicates that when the psychosis symptoms become more severe, the
amount of neurological differences from the control group increases.
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Figure 17, similar to Figure 16, displays all of the biotype comparisons overlaid with the
antipsychotics – mean comparison. This analysis was done to determine whether the use of
antipsychotics had any overall influence on all of the biotypes’ neurological functioning. The
image displays that the only main overlap was in the superior temporal gyrus, the same as Figure
16, but this overlap was not with every single one of the biotype comparisons. This is also
relevant to the article by McCarley (1993), as a greater intensity of psychosis is likely correlated
with a reduction in brain volume in the superior temporal gyrus and with the reduction in P300
potentials. These results indicate that the use of antipsychotics does not influence the
neurological functioning of all of the biotypes in the same way.
Overall, the biotype data indicates that when the psychosis symptoms are more intense,
there is some difference in brain functioning when compared to neurologically healthy
individuals. However, since there is no difference between one biotype and another, these results
are inconclusive. Further studies need to be conducted to further understand these differences in
biotype characteristics.
Table 4 is provided as a method to see whether there are any brain regions that are
implicated in the most comparisons of disorders, biotypes, or covariates. The superior frontal
gyrus and superior temporal gyrus are involved in the most comparisons, with four and five
comparisons, respectively. As it was previously expressed, the presence of these two regions in
the biotype comparisons in Table 2 indicate a similar brain functioning in Biotypes 1 and 2. This
data helps to provide the understanding that Biotype 1 exhibits some of the same functioning as
Biotype 2, but also includes some additional brain functioning differences when compared to the
control group. Besides the superior frontal gyrus and superior temporal gyrus, there are less than
three comparisons that include each brain region, which indicates that although the neurological
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functioning of each disorder and biotype is only minimally different from each other, these
differences are unique. Each disorder and biotype exhibits a unique neurological strength or
deficiency that identifies it from the other disorders and biotypes.
Finally, the comparisons in Table 3 indicate some significant results that may be worth
further analysis. The use of antipsychotics leads to an increase in functional connectivity in five
brain regions, and contrastingly the lack of using antipsychotics causes an increase in
connectivity in two other regions. Lithium intake does not impact functional connectivity, nor do
any of the PANSS scales over the subjects who do not exhibit any PANSS symptoms. Mood
medication does appear to impact functional connectivity, with two brain regions exhibiting
greater connectivity in those who take this form of medication and three regions in those who do
not. The PANSS Mean – total comparison exhibits a large number of brain regions that display
greater connectivity, indicating that individuals who do not have positive or negative psychotic
symptoms have a much greater amount of connectivity throughout the brain over those who do
exhibit both forms of symptoms.

Conclusions
Given the vague results of some parts of this research, it is clear that more research must
be conducted on the neurological implications of BPD, SZP, and SAD. BPD and SZP are
certainly entirely distinct disorders, not only from a neurological perspective but from the list of
symptoms of each disorder. BPD is more characterized as a mood disorder with the swings from
manic to depressive states, whereas SZP is more characterized by hallucinations and delusions.
Since the symptoms of SAD include some of those of the other two disorders, it makes sense that
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its neurological characteristics are undistinguishable from them. If these three disorders existed
on a spectrum, as some researchers have previously considered, SAD should be between BPD
and SZP.
Concerning the biotypes, it appears that intensity of psychosis symptoms, and the
corresponding biotypes, is impacted by some distinctions in neurological functioning. When
compared to the control groups, Biotype 1 has more neurological differences than Biotype 2, and
Biotype 2 had more differences than Biotype 3. However, when comparing the biotypes to each
other, there is no distinguishable difference in neurological functioning, so more research must
be conducted to better determine whether there is indeed any impact that neurological
functioning has on the intensity of psychosis.
In future studies, it will be necessary to include more subjects so there is a wider range of
individuals to gather conclusions from. Previous studies have provided conflicting answers on
this subject so the search for conclusive results must continue to better understand how to treat
these disorders. In addition, including other covariates to better understand other possible reasons
for the neurological differences will help gather more confident conclusions. As age of onset was
not considered in this study, it will also be necessary to analyze whether this covariate has an
impact on the neurological functioning. The age range of the subjects in this study was 15-65,
but no comparisons of age groups was included.
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